Geneva tells distributors to hold generic captopril pending resolution of Bristol hearing.
GENEVA INSTRUCTING DISTRIBUTORS TO HOLD GENERIC CAPTOPRIL pending the outcome of a hearing with Bristol-Myers Squibb over a temporary restraining order issued by a Newark federal court judge Nov. 11. The TRO came one day after the Ciba-Geigy subsidiary began shipping the generic version of Bristol's ACE inhibitor Capoten following the Nov. 9 approval of Geneva's ANDA ("The Pink Sheet" Nov. 13, T&G-1).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth